A new device developed by Indiana University researchers could revolutionize blood sugar monitoring for those with diabetes. The innovative breathalyzer technology, which doesn’t require invasive methods like finger pricks or sensors under the skin, is being hailed as a potential game-changer for millions of people managing the condition.
The device, Isaac by PreEvnt—a subsidiary of Scosche Industries—provides real-time, accurate blood sugar readings through breath analysis. It was developed through collaboration with the Integrated Nanosystems Development Institute at IU Indianapolis, inspired by diabetes alert dogs that can detect hypoglycemia in their owners. This dangerous condition, if left untreated, can lead to severe complications such as coma.
Mangilal Agarwal, director of the institute, explained that his lab successfully identified specific molecules in breath that correlate with hypoglycemia, similar to the “scent” that alert dogs detect. The team is now working on nanoscale sensors capable of identifying these molecules, with plans for commercialization.
Currently, 38.4 million Americans suffer from diabetes, according to the CDC. Managing blood sugar levels is crucial to prevent complications like kidney failure, heart attacks, and blindness. However, traditional monitoring methods, including finger pricking and continuous glucose monitors, are invasive and require frequent maintenance, making them difficult for some patients, especially younger ones.
The Isaac device aims to address these challenges by offering a non-invasive, real-time monitoring solution. Agarwal’s team is now working alongside the IU School of Medicine to validate the device’s effectiveness through clinical trials. Dr. Linda DiMeglio, an expert in pediatrics, is guiding the trials to assess the device’s accuracy compared to traditional methods.
The team hopes the device will not only serve as an alternative but also complement current technologies. For example, it could help detect low blood sugar during sleep or adjust insulin dosage for patients with portable insulin pumps. While the device’s speed and accuracy are still under review, DiMeglio noted its immediate potential in supplementing existing monitoring methods.
Agarwal and his team are determined to ensure the device can make a tangible impact on patients’ lives. Their ultimate goal is to make blood sugar monitoring more accessible, especially for children, who face a significant burden in managing the disease.
The team is also exploring the device’s potential for use in young children, who are increasingly diagnosed with diabetes. Introducing an affordable, non-invasive monitoring tool could alleviate some of the financial and emotional strain on families.
In a preliminary study, Agarwal’s lab collaborated with a diabetes camp in Indianapolis, gathering data to assess the feasibility of the breathalyzer technology. The team has since published additional findings in the journal Scientific Reports, which could help refine the device as they move forward with clinical testing.
With the ongoing trials and further development, Isaac aims to make blood sugar management simpler and more efficient, offering a breakthrough for individuals battling diabetes worldwide.
Related Topics
